EDSS

Early Treatment With Genentech’s Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile

Retrieved on: 
Wednesday, October 26, 2022
Neurology, Biotechnology, Pharmaceutical, General Health, Health, Hospitals, Clinical Trials, Other Health, Hoffmann-La Roche, Congress, Disease, MS, DMT, Multiple sclerosis, RRMS, RO, Family, Pregnancy, Patient, NEDA, HIV disease progression rates, EDSS, MRI, Treatment, PPMS, Disability, ROG, Research, RMS, Safety, ARR, Database, European Committee of the Regions, Pharmaceutical industry, Medical imaging, Genentech

The majority of patients had no relapses (93%), no MRI lesion activity (89%) and no 24-week confirmed disability progression (91%).

Key Points: 
  • The majority of patients had no relapses (93%), no MRI lesion activity (89%) and no 24-week confirmed disability progression (91%).
  • The safety profile of Ocrevus in this trial was consistent with its overall favorable safety profile.
  • Additionally, patients treated with first-line Ocrevus had lower hospitalization rates within one year compared with patients treated with second-line or later Ocrevus (0.02 vs. 0.042, respectively).
  • Tell your healthcare provider if you have had an allergic reaction to Ocrevus or any of its ingredients in the past.

EMD Serono Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment

Retrieved on: 
Wednesday, October 26, 2022
Health, Managed Care, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Immunology, Congress, Merck, RNA transfection, Multiple sclerosis, Science, OLE, MRI, University, Treatment, Hypoesthesia, Infertility, Antigen, Biomarker, SEL, MS, Gene editing, HIV disease progression rates, DBP, Inflammation, Learning, Senior, Cancer, Company, AFL, EMD, Phase, Central nervous system, Merck Millipore, BTK, Health care, Electronics, Lists of diseases, Intelligence, Research, Nerve, Microglia, CNS, ARR, European Committee of the Regions, Merck Serono, Disease, Life, Patient, EDSS, MD, Doctor of Philosophy, Â, RMS, University of Lille, Merck Group, COVID-19, Entrepreneurship, Neurodegeneration, Magnetic resonance imaging, Pharmaceutical industry, Vaccine, Medical imaging, Phosphorus, Biology, Health

In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.

Key Points: 
  • In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.
  • It also has the potential to directly address smoldering inflammation in RMS which contributes to the silent causes of disease progression.
  • It has previously shown promising results in targeting central inflammation, including through its modulatory effects on microglia.
  • Patients experienced sustained and ongoing reductions in blood NfL levels compared to the double-blind period (DBP) and OLE baseline values.

Merck Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment

Retrieved on: 
Wednesday, October 26, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Immunology, Congress, RNA transfection, Science, Multiple sclerosis, OLE, MRI, University, Treatment, GMG, Hypoesthesia, Antigen, Biomarker, SEL, Neuromyelitis optica spectrum disorder, MS, Gene editing, HIV disease progression rates, DBP, NMOSD, Inflammation, Interferon beta-1a, Learning, Senior, Company, Neurology, AFL, Phase, Central nervous system, Merck Millipore, BTK, Electronics, Lists of diseases, Intelligence, Nerve, Microglia, CNS, ARR, European Committee of the Regions, SLE, Merck Serono, Disease, Lupus, Patient, EDSS, MD, Doctor of Philosophy, Â, Research, RMS, University of Lille, COVID-19, Entrepreneurship, Neurodegeneration, Magnetic resonance imaging, Pharmaceutical industry, Vaccine, Medical imaging, Phosphorus, Merck, Biology, Health

In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.

Key Points: 
  • In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.
  • It also has the potential to directly address smoldering inflammation in RMS which contributes to the silent causes of disease progression.
  • It has previously shown promising results in targeting central inflammation, including through its modulatory effects on microglia.
  • Patients experienced sustained and ongoing reductions in blood NfL levels compared to the double-blind period (DBP) and OLE baseline values.

AB Science today reports its revenues for the first half of 2022 and provides an update on its activities

Retrieved on: 
Friday, September 30, 2022
Science, Disability, Data, Safety, COVID-19, Policy, Condition, DSMB, European Medicines Agency, THE, MRI, Review, Calendar, PPMS, European Investment Bank, Survival, FIRST, Patient, Riluzole, Committee for Medicinal Products for Human Use, AND, EDSS, Health Canada, Compliance, European Directive on Traditional Herbal Medicinal Products, Diagnosis, Magnetic resonance imaging, CHMP, Amyotrophic lateral sclerosis, WHO, ANSM, ALS, Research, Committee, NOC, EMA, Euronext, Toxicity, NSPM, Medical device, Online gambling, Pharmaceutical industry, Vaccine, Dietary supplement, Medical imaging

Under the NOC/c policy, Health Canada has a target of 200 calendar days maximum to review the application.

Key Points: 
  • Under the NOC/c policy, Health Canada has a target of 200 calendar days maximum to review the application.
  • AB Science filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in the treatment of amyotrophic lateral sclerosis (ALS).
  • In line with this recommendation, AB Science has made the decision to continue the study only in moderate patients.
  • The following table summarizes the consolidated financial statements for the first half of 2022 prepared in accordance with IFRS, and comparative information with the first half of 2021:

Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab

Retrieved on: 
Tuesday, September 20, 2022
Autoimmunity, Safety, Trial of the century, Rest, IV, COVID-19, Cytokine, Sclerosis, Principal, Expanded Disability Status Scale, Immunotherapy, Program, Patient, PET, EDSS, Crohn's disease, Neurology, Technology, Mab, BWH, Degenerative disease, SPMS, Inflammation, GLOBE, Pharmaceutical industry, Medical imaging, Regulatory T cell, Foralumab, Foralumab, Brigham

On September 12th, 2022, this patient had walked 100 meters without a cane or need for rest.

Key Points: 
  • On September 12th, 2022, this patient had walked 100 meters without a cane or need for rest.
  • SPMS represents an advanced stage of multiple sclerosis with few treatment options and creates a severe burden on patients.
  • Once a day treatment for 10 consecutive days with intranasal foralumab was both well tolerated and produced clinical responses in COVID-19 patients.
  • Tiziana Life Sciencesis a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.

Chexout Named to Inc. 5000 2022 List of Fastest Growing Private Companies

Retrieved on: 
Tuesday, August 16, 2022
STD, National Directorate for Personal Data Protection, Health, Risk, GLOBE, Emergency, Technology, COVID, National Coalition for Syrian Revolutionary and Opposition Forces, EDSS, Infection, Software as a service, Microsoft, Inc. (magazine), CDC, Contact tracing, Administration, Case management, State, Laika (EHR testing framework), Public health, Paulini, COVID-19, Public, Labs, Organization, Health care, Pharmaceutical industry, Vaccine, D.C, Oracle

The Inc. 5000 list of the fastest-growing privately held companies in the United States was first introduced by Inc. Magazine in 1982.

Key Points: 
  • The Inc. 5000 list of the fastest-growing privately held companies in the United States was first introduced by Inc. Magazine in 1982.
  • Over the years, the Inc. 5000 list has become a measure of entrepreneurial success in the United States.
  • Companies on the 2022 Inc. 5000 have been ranked according to percentage revenue growth from 2018 to 2021. Notable companies previously named to the list include Microsoft, Oracle, Under Armour, Pandora, and Patagonia.
  • The Inc. 5000 recognition puts Chexout in the top 0.00003 of all privately owned companies in America in terms of multi-year growth.

Bragar Eagel & Squire, P.C. Is Investigating Fulgent, Generac, Atara, and Clariant and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, August 16, 2022
Industry, NYSE, GLOBE, Anti-Kickback Statute, SEC, DOJ, Securities Exchange Act of 1934, EDSS, Disability, ATRA, Remuneration, Battle of Saint-Fulgent, Genetics, Patient, Company, Acquisition, Generac Holdings, Data, Partnership, Fraud, Awareness, Exchange, NASDAQ, News, IA, FTC, Stark, Pharmaceutical industry, Online gambling, Audit, P.C, Clariant

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • As part of its release, the Company disclosed that the SEC is investigating certain Exchange Act reports for 2018 through the first quarter of 2020.
  • Based on this news, shares of Fulgent fell by $3.34 per share, or 5.3%, to close at $59.86 per share on August 5, 2022.
  • On this news, shares of Clariant AG ADR shares fell more than 14% in intraday trading on February 14, 2022.

ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, August 6, 2022
Class Action Lawsuit, Professional Services, Legal, P.C, Telephone, Industry, EDSS, Disability, ATRA, Patient, Company, Data, Awareness, NASDAQ, Jeanne Eagels, News, IA, Private investigator, Pharmaceutical industry

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.
  • Our investigation concerns whether Atara has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On November 4, 2021, Atara issued a press release touting its T cell immunotherapy product candidate, ATA188.
  • In this release, the Company claimed that there was "positive momentum around the ATA188 program" and "increasing awareness of and excitement .

Bragar Eagel & Squire, P.C. Is Investigating TuSimple, Atara, Mercury, and the WWE and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, August 6, 2022
Hush, P.C, Travel, Federal Motor Carrier Safety Administration, Mercury Systems, Industry, NYSE, GLOBE, CEO, Female, WWE, Mercury, EDSS, The Wall Street Journal, Disability, Board, ATRA, Compliance, Patient, Company, McMahon, Acquisition, Data, Glass house, MRCY, Safety, Awareness, NASDAQ, Physical optics, Institutional review board, News, IA, Journal, Audit, Pharmaceutical industry, Animal

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • The article alleges that one of the Companys autonomously driven trucks left its lane of travel without warning before striking a cement barricade.
  • The article also reveals that the Federal Motor Carrier Safety Administration has launched a safety compliance investigation.
  • For more information on the WWE investigation go to: https://bespc.com/cases/WWE
    About Bragar Eagel & Squire, P.C.

ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, August 5, 2022
Class Action Lawsuit, Professional Services, Legal, P.C, Telephone, Industry, EDSS, Disability, ATRA, Patient, Company, Data, Awareness, NASDAQ, Jeanne Eagels, News, IA, Private investigator, Pharmaceutical industry

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.
  • Our investigation concerns whether Atara has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On November 4, 2021, Atara issued a press release touting its T cell immunotherapy product candidate, ATA188.
  • In this release, the Company claimed that there was "positive momentum around the ATA188 program" and "increasing awareness of and excitement .